We are happy to announce key milestones in our ongoing clinical program: RHEACELL receives EMA approval for allo-APZ2-CVU Phase 3 trial in chronic venous ulcers You will always find our press releases, interesting literature and the newest scientific papers and on our website using the following link: https://lnkd.in/ggCNBKx4
RHEACELL GmbH & Co. KG’s Post
More Relevant Posts
-
🎉 EMA Approves RHEACELL’s Phase 3 CVU Trial! We’re excited to announce EMA approval for our allo-APZ2-CVU Phase 3 trial in chronic venous ulcers (CVU). This multi-center, double-blinded study will evaluate our ABCB5+ stem cell therapy in 250 patients across 100+ sites. A pivotal step toward innovative treatments for patients with unmet needs! #EMAApproval #Phase3 #StemCellTherapy #ChronicVenousUlcers #RHEACELL
We are happy to announce key milestones in our ongoing clinical program: RHEACELL receives EMA approval for allo-APZ2-CVU Phase 3 trial in chronic venous ulcers You will always find our press releases, interesting literature and the newest scientific papers and on our website using the following link: https://lnkd.in/ggCNBKx4
Keeping research up-to-date – latest developments hot off the press!
rheacell.com
-
The practice of evaluation creates opportunities to adapt, improve and respond. This publication in the Journal of Clinical and Translational Science details the impact of evaluators and their roles within the CTSA consortium. Takeaways include CTSA consortium knowledge in evaluation, best practices, evidenced-based recommendations for evaluation practice (at both national and group-level), and prompt use by other large evaluation consortia. Read more here: https://ow.ly/HYuC50Up8vh #CTSAProgram
Landscape Assessment of CTSA Evaluators Highlights Strengths, Opportunities
nucats.northwestern.edu
-
ICTER is becoming ICTER CoE! The International Centre for Translational Eye Research (ICTER) is one of the winners of the prestigious "Teaming for Excellence" in the European Commission's Horizon Europe programme. Thanks to the funding of 15 million euros, a Centre of Excellence (ICTER CoE) will be established, operating at the Institute of Physical Chemistry, Polish Academy of Sciences and headed by Prof. Maciej Wojtkowski. The ICTER Centre of Excellence's goals, i.e. creating modern ophthalmic diagnostic tools to combat eye diseases affecting over 250 million people worldwide, will remain the same, but will now be pursued on an incomparably larger scale. More information about the newly established Centre of Excellence: https://lnkd.in/d8wD7aVq. #ICTER_PL #IPC_PAS #IChF #CentreofExcellence #TeamingforExcellence #Grant #Widening #HorizonEurope #EUFunds #EUCommision #Vision
-
-
ABSTRACT DEADLINE TODAY - OIFE INVESTIGATOR MEETING The deadline to submit abstracts to our online Investigator Meeting is today Friday, 4 October 23:59 CET. We invite your abstracts on any aspect of OI research, whether basic, translational or clinical. A limited number of oral slots are available on the programme and priority will be given to abstracts describing novel research and hot topics related to OI. We also encourage submission of case reports for discussion at the meeting. Please use the same form to submit any interesting and/or unusual cases. Presentations will not be recorded or streamed outside of the webinar and abstracts will not be published, enabling the presentation and discussion of unpublished data. Link to submit abstracts and registration can be found here: https://lnkd.in/dzHDb8ra #osteogenesisimperfecta
-
-
Dr. Abdullah Al Maruf from University of Manitoba is editing an issue on the clinical implementation of pharmacogenomics. Learn more about this new issue and submit your paper before 25th December: 🔗https://lnkd.in/db53BvSC
-
-
Genomics Sequencing Technical Consultant | Strategic Partner Project Management | Customer Relations
Check out Weill Cornell Medicine's first annual Cores Day on 01/14! PacBio is proud to be a technology partner supporting the WCM research community. There are opportunities for attendees to save on services. Don't miss out! Here are a few examples of what you can achieve on the Revio system at WCM: HiFi WGS with 5mC, 500ng input, 120Gb HiFi yield; Full-length cDNA sequencing, bulk or single-cell: a fuller picture of the transcriptome; Best-in-class and cost-effective solution for microbial sequencing, whether it's for isolates, communities, or 16S/ITS amplicons. See agenda and participating cores: https://lnkd.in/e44wms8d
First Annual Weill Cornell Medicine Cores Day
research.weill.cornell.edu
-
Did you know contents in the Investigator Brochure. The IB is a critical tool in clinical research, ensuring that investigators have all the necessary information to conduct the trial ethically and safely. It helps investigators understand the scientific rationale, the potential benefits, and the risks associated with the investigational product. This comprehensive document supports informed decision-making and safeguards the well-being of trial participants. Satish Marukurthi Jacob Odika Apollo
-
Are you doing any research on osteogenesis imperfecta? We need your abstracts to our upcoming online OIFE Investigator Meeting. We invite your abstracts on ANY aspect of OI research, whether basic, translational or clinical. A limited number of oral slots are available on the programme and priority will be given to abstracts describing novel research and hot topics related to OI. #osteogenesisimperfecta
OIFE INVESTIGATOR MEETING - ABSTRACT DEADLINE OCTOBER 4 We have 77 registered people who signed up to attend our online investigator meeting. But there is room for more. Sign up and tell your colleagues to do the same! The meeting takes place via Zoom on Friday 15 November from 14:00-19:00 CET. We remind you to submit your abstracts latest Friday, 4 October 23:59 CET. We invite your abstracts on any aspect of OI research, whether basic, translational or clinical. A limited number of oral slots are available on the programme and priority will be given to abstracts describing novel research and hot topics related to OI. We also encourage submission of case reports for discussion at the meeting. Please use the same form to submit any interesting and/or unusual cases. Presentations will not be recorded or streamed outside of the webinar and abstracts will not be published, enabling the presentation and discussion of unpublished data. This is an opportunity for you to present and discuss your OI-related work with an international group of fellow OI-researchers in a relatively informal setting and without the costs and time involved in travelling to in-person meetings. The aim is to facilitate collaboration and development of research in OI. Link to submit abstracts and registration can be found here: https://lnkd.in/dzHDb8ra #osteogenesisimperfecta
-
-
Happy #GlobalBiosimilarsWeek! Check out Biologics & Biosimilars Collective Intelligence Consortium (BBCIC)'s timeline for useful insights and information about the world of #biosimilars.
As we celebrate #GlobalBiosimilarWeek 2024, hear from AMCP's Chief Science Officer & Executive Director of BBCIC, Cate Lockhart, PharmD, PhD about what AMCP is doing to participate in the development of #biosimilars across the world. Learn more: https://bit.ly/48F8pkg
-
Aspiring Scientist | Research Assistant, Exercise Physiology & Biomarkers Laboratory/ NUS Healthy Longevity Translational Research Program/NUHS Centre for Healthy Longevity
Ecstatic to report that the protocol paper for our current clinical study has been published! Looking forward to report our interesting findings. I would like to thank Jorming G. for the opportunity to publish my first article as a first author and looking forward to more publications together! #exercisephysiology&biomarkerslaboratory #epblaboratory #nus
-
